Literature DB >> 20025433

Ocular ciprofloxacin hydrochloride mucoadhesive chitosan-coated liposomes.

Ghada Abdelbary1.   

Abstract

The aim of this work is to improve the ocular bioavailability of ciprofloxacin hydrochloride (CPX) through the preparation of ocular mucoadhesive chitosan (CS)-coated liposomes. Liposomes were prepared by the thin film hydration technique, using different molar ratios of L-α-phosphatidylcholine (PC), cholesterol (CH), stearylamine (SA) and dicetyl phosphate (DP). CS was used to coat the optimal liposomal formulae. The prepared formulae were characterized regarding encapsulation efficiency (%EE), particle size, physical morphology and in vitro drug release. The in vivo characterization of the prepared formulae was performed through evaluating the level of CPX in the external eye tissue of nine albino rabbits. Results showed an alteration in release rate and %EE of CPX from liposomal formulae upon varying the molar ratios of the lipid bilayer composition. The optimal liposomal formulae F1 (10:0, PC:CH), F12 (10:0:0.5, PC:CH:SA) and F15 (10:0:1, PC:CH:DP), showed % EE of 38.5 ± 2.10, 39.65 ± 1.85 and 30.05 ± 0.75 and % in vitro release after 8 hours (Q(8h)) of 78.15 ± 2.4, 54.07 ± 2.3 and 62.14 ± 2.9, respectively. In vitro drug release and in vivo results confirmed that CS-coated liposomal formulae have exhibited a higher retention of CPX. Consequently, CS-coated liposomes could be a promising approach to increase the ocular bioavailability of CPX.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20025433     DOI: 10.3109/10837450903479988

Source DB:  PubMed          Journal:  Pharm Dev Technol        ISSN: 1083-7450            Impact factor:   3.133


  13 in total

1.  Design of liposomal colloidal systems for ocular delivery of ciprofloxacin.

Authors:  Ehab I Taha; Magda H El-Anazi; Ibrahim M El-Bagory; Mohsen A Bayomi
Journal:  Saudi Pharm J       Date:  2013-08-08       Impact factor: 4.330

2.  Development and optimization of novel controlled-release pioglitazone provesicular powders using 3² factorial design.

Authors:  Marwa H Shukr; Nadia A Eltablawy
Journal:  Drug Deliv Transl Res       Date:  2015-02       Impact factor: 4.617

Review 3.  Recent patents on ophthalmic nanoformulations and therapeutic implications.

Authors:  Ann-Marie Ako-Adounvo; Ramesh C Nagarwal; Lais Oliveira; Sai H S Boddu; Xiang S Wang; Surajit Dey; Pradeep K Karla
Journal:  Recent Pat Drug Deliv Formul       Date:  2014

4.  Sustained-release genistein from nanostructured lipid carrier suppresses human lens epithelial cell growth.

Authors:  Jin-Lu Liu; Wen-Ji Zhang; Xue-Dong Li; Na Yang; Wei-San Pan; Jun Kong; Jin-Song Zhang
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

5.  Ocular drug delivery systems: An overview.

Authors:  Ashaben Patel; Kishore Cholkar; Vibhuti Agrahari; Ashim K Mitra
Journal:  World J Pharmacol       Date:  2013

6.  Evaluation of Metformin Hydrochloride Tailoring Bilosomes as an Effective Transdermal Nanocarrier.

Authors:  Heba F Salem; Mohammed M Nafady; Adel A Ali; Nermeen M Khalil; Amani A Elsisi
Journal:  Int J Nanomedicine       Date:  2022-03-17

7.  Recent applications of liposomes in ophthalmic drug delivery.

Authors:  Gyan P Mishra; Mahuya Bagui; Viral Tamboli; Ashim K Mitra
Journal:  J Drug Deliv       Date:  2011-03-01

8.  Chitosan temperature-sensitive gel loaded with drug microspheres has excellent effectiveness, biocompatibility and safety as an ophthalmic drug delivery system.

Authors:  Xiaoying Kong; Wenhua Xu; Cuiping Zhang; Wei Kong
Journal:  Exp Ther Med       Date:  2017-12-01       Impact factor: 2.447

Review 9.  Advanced drug delivery and targeting technologies for the ocular diseases.

Authors:  Jaleh Barar; Ayuob Aghanejad; Marziyeh Fathi; Yadollah Omidi
Journal:  Bioimpacts       Date:  2016-03-30

Review 10.  Ophthalmic Drug Delivery Systems for Antibiotherapy-A Review.

Authors:  Marion Dubald; Sandrine Bourgeois; Véronique Andrieu; Hatem Fessi
Journal:  Pharmaceutics       Date:  2018-01-13       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.